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Abstract: PURPOSE To evaluate early changes in retinal layers using optical coherence tomography
(OCT) in patients with long-standing type 1 diabetes (DM1) receiving intensified insulin therapy. METH-
ODS In a cross-sectional case-control study 150 patients with DM1 and 150 age- and sex-matched healthy
control participants underwent OCT imaging. Scans of both eyes were analysed for different layers (NFL,
GCL (+IPL), INL, outer layer complex (OLC, including OPL, ONL and ELM) and photoreceptors (PR))
in all subfields of an ETDRS grid. All analyses were performed semi-automatically using custom soft-
ware by certified graders of the Vienna Reading Center. ANOVA models were used to compare the mean
thickness of the layers between patients and controls. RESULTS Six hundred eyes with 512 datapoints
in 49 b-scans in each OCT were analysed. Mean thickness in patients/controls was 31.35 ฀m/30.65 ฀m
(NFL, p = 0.0347), 76.7 ฀m/73.15 ฀m (GCL, p ฀ 0.0001), 36.29 ฀m/37.13 ฀m (INL, p = 0.0116), 114.34
฀m/112.02 ฀m (OLC, p < 0.0001) and 44.71 ฀m/44.69 ฀m (PR, p = 0.9401). When evaluating the ETDRS
subfields separately for clinically meaningful hypotheses, a significant swelling of the GCL in patients
could be found uniformly and a central swelling for the OLC, whereas the distribution of NFL and INL
thickening suggests that their statistical significance was not clinically relevant. CONCLUSION These
preliminary results demonstrate that preclinical retinal changes in patients with long-standing DM1 can
be found by retinal layer evaluation. However, the changes are layer-specific, with significant thickening
of the GCL and less so of the OLC suggesting a role as an early sign for diffuse swelling and the evolution
of DME even in well-controlled diabetes.
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ABSTRACT.
Purpose: To evaluate early changes in retinal layers using optical coherence
tomography (OCT) in patients with long-standing type 1 diabetes (DM1)
receiving intensified insulin therapy.
Methods: In a cross-sectional case–control study 150 patients with DM1 and 150
age- and sex-matched healthy control participants underwent OCT imaging. Scans of
both eyes were analysed for different layers (NFL, GCL (+IPL), INL, outer layer
complex (OLC, including OPL, ONL and ELM) and photoreceptors (PR)) in all
subfields of an ETDRS grid. All analyses were performed semi-automatically using
custom software by certified graders of the Vienna Reading Center. ANOVA models
were used to compare the mean thickness of the layers between patients and controls.
Results: Six hundred eyes with 512 datapoints in 49 b-scans in each OCT were
analysed. Mean thickness in patients/controls was 31.35 lm/30.65 lm (NFL,
p = 0.0347), 76.7 lm/73.15 lm (GCL, p ≤ 0.0001), 36.29 lm/37.13 lm (INL,
p = 0.0116), 114.34 lm/112.02 lm (OLC, p < 0.0001) and 44.71 lm/44.69 lm
(PR, p = 0.9401). When evaluating the ETDRS subfields separately for clinically
meaningful hypotheses, a significant swelling of the GCL in patients could be found
uniformly and a central swelling for the OLC, whereas the distribution of NFL and
INL thickening suggests that their statistical significance was not clinically relevant.
Conclusion: These preliminary results demonstrate that preclinical retinal
changes in patients with long-standing DM1 can be found by retinal layer
evaluation. However, the changes are layer-specific, with significant thickening
of the GCL and less so of the OLC suggesting a role as an early sign for diffuse
swelling and the evolution of DME even in well-controlled diabetes.
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As early as in the 1980s, the population-
based Wisconsin Epidemiologic Study of
Diabetic Retinopathy (WESDR) demon-
strated a prevalence of diabetic retinopa-
thy (DR) of 17% in patients with
diabetes of less than 5 years and 97.5%
of 15 or more years duration (Klein et al.
1984). Patients with recently diagnosed
type 1 diabetes (DM1) had a lower risk
for sight-threatening stages of DR such
as proliferative diabetic retinopathy and/
or diabetic macular oedema (DME) than
those diagnosed longer before (Hovind
et al. 2003; Nordwall et al. 2004). Strict
blood-sugar control by intensified insulin
therapy reduced the risk of developing
microvascular diabetes complications
such as DR, especially the late stages
(The Diabetes Control and Complica-
tions Trial Research Group 1993; Fuller-
ton et al. 2014). However, DR is still one
of the leading causes of vision loss in
adults aged 20–74 years (Cheung et al.
2010), which may lead to patients with
DM1 retiring early (Gomes & Negrato
2015). Despite advances in diabetes care,
many patients have complications for
variousreasons.Therefore,greaterempha-
sis must be placed on a better understand-
ing of the mechanisms by which diabetes
affects the retina and early signs of diabetic
retinal changes.
Optical coherence tomography (OCT)
technology has markedly improved the
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qualitative and quantitative evaluation
of pathologic retinal changes in DR,
especially in DME. Quantitative evalua-
tions such as central retinal thickness
(CRT) have become markers for evalu-
ating treatment efficacies in clinical stud-
ies (Csaky et al. 2008). However, CRT is
only modestly correlated with visual
acuity in DME and sometimes visual
acuity does not follow CRT improve-
ment or worsening (Browning et al.
2007; Gerendas et al. 2014). With the
introduction of spectral-domain (SD)
and swept-source OCT technology with
higher resolution, speed and reduced
speckle noise, we can obtain images with
more detailed information. Typical
lesions in progressed DR/DME such
as intraretinal cystoid fluid, subretinal
fluid and hyper-reflective foci are easy
to detect but discreet depth changes in
mild DR or subclinical stages of DR are
not obvious. Earlier studies concluded
that at least thickness measurements in
time-domain OCT are unhelpful in early
DR (Ciresi et al. 2010). Today, auto-
mated algorithms, for example layer seg-
mentation software, make quantifying
the thickness of individual retinal layers
and qualitatively evaluate lesions in each
layer possible. Such early changes in DR
on OCT, particularly retinal layer seg-
mentation features, have been examined
in animal models and clinically. In early
diabetic mice, retinal thinning found by
OCT corresponded to outer nuclear layer
(ONL) thinning in histological sections
when vascular changes were not visible in
fluorescein angiography (FA) images
(Yang et al. 2015). In diabetes mellitus
type 2 (DM2), thinning of inner retinal
layers, including the ganglion cell and
inner plexiform layer (GCIPL) complex
and retinal nerve fibre layer (NFL) was
reported by several authors comparing
the results of patientswith different stages
of DR and healthy control participants
(van Dijk et al. 2012; Chhablani et al.
2015; Carpineto et al. 2016). The reduc-
tion inNFLthicknesswas confirmed, and
a central increase in inner nuclear layer
(INL) and outer plexiform layer (OPL)
thickness found in a mixed DM1 and
DM2 population while the GCIPL and
inner retinal layer thicknesses showed no
significant difference to the study’s con-
trol group (Vujosevic & Midena 2013).
As patients with DM1 show differ-
ent patterns of complications, includ-
ing compared with DM2 (Cusick et al.
2005) differences within the early OCT
changes between these patients may
exist, too. But thinning of the ganglion
cell layer and the GCIPL complex,
respectively, has also been found com-
paring patients with DM1 and healthy
groups (van Dijk et al. 2009, 2010;
Chen et al. 2016). Furthermore, total
retinal thickness was reported as already
reduced in patients with only minimal
DR and/or after a short duration of
DM1 compared with healthy groups
(Biallosterski et al. 2007; Chen et al.
2016). Inner nuclear layer (INL) was
thinner in DM1 than in control groups
(van Dijk et al. 2009; Chen et al. 2016;
Stem et al. 2016) and increased glycemic
variability correlated with retinal thin-
ning (Stem et al. 2016).
This study was designed to analyse
retinal layer thicknesses in SD-OCT
images within all ETDRS subfields in a
DM1 population treated with intensi-
fied insulin therapy from disease diag-
nosis and compare the results with
those of a healthy control group
matched to it 1:1 for age and sex.
Material and methods
Study participants
Data sets for this study subanalysis were
from a cross-sectional study of patients
with DM1 and healthy control partici-
pants recruited at the outpatient clinic at
the Department of Diabetology/
Endocrinology of the University Hospital
Basel and the Department of Diabetol-
ogy/Endocrinology of the University
Hospital Zurich between August 2010
and May 2014. Inclusion criteria for
patients for the core study were age of
>18 years, DM1 for ≥5 years and
≤30 years and treatment with intensified
insulin therapy since disease diagnosis.
Exclusion criteria were unsuitability for
fluorescein angiography, uncontrolled
hypertension and a change in antihyper-
tensive treatment within 2 months pre-
enrolment, pregnancy, any disease that
could render the quality of images insuf-
ficient (e.g. cataract).
The control group was matched 1:1
for age and sex to the patient group.
Exclusion criteria were any ocular dis-
ease or medication known to compro-
mise retinal structure, history of
diabetes, arterial hypertension or any
systemic disease or medication known to
compromise retinal structure, pregnancy,
any disease that could render the quality
of images insufficient (e.g. cataract).
All participants agreed to take part
in the study and signed an informed
consent form before the study. The
study was approved by the local ethics
committees (Ethikommission Nord-
westschweiz: BS 81/10; Kantonale
Ethikkommission Zuerich: KEK-ZH
2012-0050), conducted in compliance
with ICH GCP and adhered to the
tenets of the Declaration of Helsinki. It
was registered at clinicaltrials.gov as
NCT02307110.
Examinations
Best-corrected visual acuity (BCVA),
fundus biomicroscopy, intraocular eye
pressure, standard 7-field colour fundus
photographs and fluoresceine angiogra-
phy performed in the core study were
not part of this subanalysis. All OCT
images were recorded at a Heidelberg
Spectralis (Heidelberg Engineering, Hei-
delberg, Germany) SD-OCT device
located at Vistaklinik, Binningen,
Switzerland (patients and controls) or
at Vista Diagnostics, Zurich, Switzer-
land (patients only) by one trained and
reading center-certified ophthalmologic
photographer (CK). The scan protocol
comprised macular raster scans of both
eyes in the high-speed mode, a
20° 9 20° recording field (equivalent
to 6 9 6 mm) with 49 b-scans (inter-
scan distance 125 lm) and an averaging
of 15 frames per b-scan.
OCT image analysis
All OCT images were analysed at the
independent, fully digitalized Vienna
Reading Center to provide a uniform,
standardized and accurate assessment.
Validated computer-assisted custom
grading software was used. Graders
were trained according to a standard-
ized predefined study protocol and
received regular supervision for train-
ing and quality control.
Five different layers were evaluated in
OCT scans of both eyes: NFL (layer 1),
a complex of the GCIPL (layer 2), INL
(layer 3), a complex of the outer plexi-
form layer, outer nuclear layer, external
limiting membrane until photoreceptor
inner segments begin, referred to as the
outer layer complex (OLC, layer 4) and
photoreceptors (PR, layer 5). These five
layers were evaluated in all subfields of a
fovea-centred early treatment diabetic
retinopathy study (ETDRS) grid. Fig-
ure 1 shows an example.
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First, each of 49 b-scans was loaded
and checked for image quality and the
possibility to evaluate each of the
layers. If an entire raster scan was of
poor image quality the patient-control
pair was excluded. Single b-scans of
insufficient quality were excluded. If a
region of a-scans within a b-scan could
not be evaluated due to an artefact, a
vessel shadow, etc., this region was
excluded (Fig. 2 shows examples).
Afterwards, an ETDRS grid was
positioned on the foveal centre point
(see Fig. 1). An automated layer seg-
mentation at the Vienna Reading Cen-
ter was used as a starting point for
layer segmentation. Each layer was
then manually adjusted on each b-scan
and deleted. If the automated segmen-
tation was too poor, the layer was
solely manually segmented. Therefore,
the segmentation can be described as a
manually assisted.
Statistical analysis
Three-way analysis of variance
(ANOVA) models were used to com-
pare the mean thickness of the OCT
layers of both eyes between patient and
healthy participants.
The dependent variable mean thick-
ness, group variable patient/control,
and factors layer (NFL, GCL, INL,
OLC and PR) and the nine different
standard ETDRS grid subfields were
considered in the ANOVA model for
evaluation. The variable partner match
was included as a random block factor
to consider the 1:1 matching of patients
and controls and the variable subject
was included as a nested random factor.
To evaluate whether differences between
the two vary between the five different
layers and between the nine different
ETDRSgrid subfields, respectively, inter-
action terms were included in the
ANOVAmodel. Due to statistical signif-
icance of these interaction terms, the
group effects (patients vs. controls) were
tested separately for each layer and each
ETDRS grid subfield, respectively. Fur-
thermore, subgroup analyses were per-
formed evaluating the layers NFL, GCL,
INLandOLC, separately, with respect to
the different group effects in the ETDRS
grid subfields, using two-way ANOVA
models. Differences in the group effects
depending on the ETDRS grid subfield
were again evaluated by testing the
respective interaction. Least squares
(LS) means and the differences between
LSmeans (with 95% confidence intervals
(CI)) are given to describe the size of the
group effects (patients versus controls).
Extreme outliers (=observations with stu-
dentized residuals outside the range of5
in the ANOVA model) were excluded
from the analysis. To test for group effects
in the intra-individual difference between
the two eyes of the same participant, a
three-way ANOVA model was used,
considering the log-transformed absolute
difference between the right and the left
eye as a dependent variable. Two-sided p-
values of <0.05 were interpreted as statis-
tically significant. Due to the exploratory
character of this study no correction for
multiple testing was performed.
As a side note, the primary statistical
analysis was performed in the entire
ETDRS grid only. This resulted in
many statistically significant findings
as a large number of data points were
tested; therefore, all values were evalu-
ated for their clinical relevance. The
following clinical hypotheses led to the
described subgroup analyses for layers
NFL, GCL, INL and OLC:
Hypothesis
Due to the natural distribution of the
NFL, the ETDRS grid subfield outer
nasal,whichcontainsusuallythethickest
NFL (nearest to optic disc), shows a
relatively larger difference inNFL thick-
ness that is decreasing across the sub-
fields from nasal to temporal areas,
showing the smallest difference in the
outer temporal ETDRS grid subfield,
whichusually contains the thinnestNFL
(furthest away from optic disc).
Hypothesis
A swelling in the GCL is seen in all
ETDRS subfields as cysts in the
Fig. 1. Example central b-scan of optical coherence tomography with five evaluated layers,
showing from top to bottom nerve fibre layer (NFL, layer 1), a complex of the ganglion cell and
inner plexiform layers (GCL, layer 2), inner nuclear layer (INL, layer 3), a complex of the outer
plexiform layer, outer nuclear layer, external limiting membrane until photoreceptor inner
segments begin, referred to as the outer layer complex (OLC, layer 4) and photoreceptors (PR,
layer 5); vertical lines are circles of early treatment diabetic retinopathy study grid in en-face view
(yellow = foveal centre point, light blue = central millimetre subfield, blue = central 3 mm
circle subfields, dark blue = 6 mm circle subfield; yellow segmentation lines are original lines
from automated segmentation, green segmentation lines show where segmentation has been
corrected by the Vienna Reading Center.
Fig. 2. Two example b-scans of optical coherence tomography with excluded areas due to vessels
and vessel shadows. Left top and bottom: original b-scans, right top and bottom: corresponding b-
scans with excluded areas (green, layer segmentation and horizontal grid lines for subfield).
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ganglion cell layer appear without a
relation to the centre and a swelling
could be a diffuse macular oedema.
Hypothesis
A swelling in the INL and OLC is seen
more prominently in the central sub-
field(s) as cysts in the inner and outer
nuclear layers appear usually close to
the fovea and this swelling could be a
first sign of arising DME.
Results
Patient characteristics
One hundred and fifty patients and 150
age- and sex-matched healthy control
participants in each group presented
with a mean age of 40  14 years, a
2:1 male (n = 97) to female (n = 53)
ratio, and in the patient group a mean
duration of diabetes of 14  6 years
(range 5–29 years), were included in
this analysis. Patients were perfectly
controlled metabolically with a mean
blood pressure of 124  14 mmHg/
77  10 mmHg and a median HbA1c
of 7.4% [interquartile range 6.8–8.1%].
On fundus images, 75.3% of eyes (of 49
patients, 25 both eyes) showed no or
only mild signs of DR and 24.7%
higher stages of DR. 0.03% of eyes
showed intraretinal cystoid fluid (nine
eyes of seven patients) and 0.003%
subretinal fluid (1 eye). Morphologic
grading showed that no macular
oedema was present except for singular
small cystoid spaces. Interestingly,
seven eyes (five controls) also showed
such intraretinal cystoid fluid on
OCT, although the inclusion criteria
were fulfilled. Mean total retinal
thickness in the central ETDRS grid
subfield was 266 lm in patient and
263 lm in control participants.
Table S1 shows total retinal thickness
values (and standard deviations) of all
ETDRS grid subfields. A precise
description of the colour fundus and
fluorescein angiography results and
their correlation with systemic vari-
ables is published elsewhere (Hatz
et al. 2019).
Statistical analysis was performed with
and without inclusion of the 16 eyes with
retinal fluid with no relevant difference
between the results. The duration of
diabetes was also tested as a covariable
and no significant impact was found
(p = 0.45). Here, the results are reported
where eyes with retinal fluid were
excluded and no correction for diabetes
duration made, as described in the
prospectively planned statistical analysis.
OCT layer thicknesses – descriptive
overview
In total, 25 470 observation points (a-
scan thicknesses) were segmented. The
following section describes the data
without exclusion of outliers. Figure 3
shows box plots of mean layer thick-
nesses in the entire ETDRS grid of each
layer for patient versus control groups.
The differences between patient and
control groups are already very small
compared with the total variance of the
data. The mean thickness (standard
deviation) of the central millimetre sub-
field for the control andpatient groups is
14.06  1.52 lm and 11.51  2.98 lm
for the NFL, 36.48  8.39 lm and
39.6  10.40 lm for the GCIPL, 20.97 
5.5 lmand21.40  4.69 lmfor the INL,
138.6 10.23 lmand141.84  12.72lm
for the OLC, and 52.46  3.67 lm and
51.45  3.99 for the PR. Table S1 shows
values of all ETDRS subfields’ mean
thicknesses of the patient and control
groups.
ANOVA model for the entire ETDRS grid
Eight observation points were excluded
from the ANOVA model as extreme
outliers (8/25 470 = 0.03%). Overall,
therewas a significant difference inmean
thickness for patient versus control par-
ticipants (p = 0.0003). As expected,
there was also a highly significant differ-
ence between thicknesses in different
ETDRS subfields (p < 0.0001) and dif-
ferent layers (p < 0.0001). A highly sig-
nificant difference of the group effect
(patients versus controls) was found
between the different layers (p < 0.0001).
The difference [95% confidence interval]
of the estimated LS-means (controls
minus patients) was 0.7 lm [1.34;
0.05] for NFL (i.e. controls in mean
thinner than patients, p = 0.0347),3.54
lm [4.2;2.9] for GCL (i.e. controls in
mean thinner than patients, p < 0.0001),
0.83 lm [0.19; 1.48] for INL (i.e. controls
in mean thicker than patients,
p = 0.0116), 2.32 lm [2.97; 1.67]
for OLC (i.e. controls in mean thinner
than patients, p < 0.0001) and around
zero (0.02 [0.67; 0.62], no significant
difference, p = 0.9401) for PR.
In absolute values, the estimate for
the layer thicknesses (LS-mean) of
patient vs. control participants in the
entire ETDRS grid was 31.35 lm ver-
sus 30.65 lm for NFL, 76.7 lm versus
73.15 lm for GCIPL, 36.29 lm versus
37.13 lm for INL, 114.34 lm versus
112.02 lm for OLC and 44.71 lm
versus 44.69 lm for PR.
The total retinal thickness in the
ETDRS grid subfields (which is the
mean summarized thickness of the 5
layers in each subfield for all 300 study
participants) was lowest with 263 lm
in the central millimetre subfield of
controls and highest with 336 lm in
the inner nasal subfield of patients. The
estimated mean thicknesses (LS means)
in the ETDRS grid subfields were
always lower in the control than in
patient group and the differences ranged
from 3.56 to 12.24 lm with signifi-
cances (p = 0.0362 to p < 0.0001). This
overall thickening in patients was more
pronounced in the outer subfields.
Table 1 gives the exact numbers in all
subfields. In addition, no significant
difference between patient and control
participants regarding the intra-individ-
ual difference between the right and left
eye (p = 0.1388) was found. Therefore,
values for all 600 eyes remained in the
statistical analysis.
ANOVA model for separate ETDRS grid
subfields
Nerve fibre layer
There was a highly significant differ-
ence in the group effect (patients versus
controls) between different ETDRS
grid subfields (p < 0.0001) in the
NFL. The differences [95% confidence
interval] of the estimated LS means
(controls minus patients) for the five
subfields from the outer temporal to
outer nasal line were 0.80 lm [1.60;
0.002], p = 0.0504 (outer temporal);
0.42 lm [1.22; 0.38], p = 0.2992
(inner temporal); 2.51 lm [1.71; 3.31],
p < 0.0001 (central subfield); 1.06 lm
[1.86; 0.26], p = 0.0094 (inner
nasal);and 2.29 lm [3.09; 1.48],
p < 0.0001 (outer nasal). In absolute
values, the estimate for the NFL thick-
nesses (LS means) of patient versus
control participants for each ETDRS
grid subfields was 22.19 lm versus
21.4 lm (outer temporal), 20.8 lm ver-
sus 20.38 lm (inner temporal),
11.54 lm versus 14.05 lm (central mil-
limetre) 25.72 lm versus 24.66 lm
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(inner nasal) and 55.19 lm versus
52.9 lm (outer nasal). This rejects
Hypothesis 1 and indicates a statistical
significance with no clinical relevance.
Ganglion cell layer and inner plexiform
layer complex
Again a highly significant difference
was found in the group effect (patients
versus controls) between different
ETDRS grid subfields (p = 0.0002) in
the GCIPL. The differences [95%
confidence interval] of the estimated
LS means (controls minus patients) for
the nine ETDRS subfields were all
between 2.52 lm [3.92; 1.13] (in-
ner temporal) and 5.15 lm [6.54;
3.76] (outer nasal), all p < 0.0001,
except inner temporal p = 0.0004).
Table 2 shows values of all ETDRS
subfields, including absolute values.
These findings support Hypothesis 2
and a diffuse swelling of the GCIPL in
the patient group.
Inner nuclear layer
There was also a highly significant
difference in the group effect (patients
versus controls) between different
ETDRS grid subfields (p < 0.0001) in
the INL. The differences [95% confi-
dence interval] of the estimated LS-
means (controls minus patients) for the
nine ETDRS subfields were all between
0.58 lm [1.31; 0.15] (central) and
1.89 lm [1.16; 2.62] (inner bottom),
with some significant and some non-
significant p-values. Table 2 shows val-
ues of all ETDRS subfields, including
absolute values and p-values. These
findings reject Hypothesis 3 for INL
and a diffuse swelling of the INL in the
patient group and indicate a statistical
significance with no clinical relevance.
Outer layer complex, including the outer
nuclear layer
There was a highly significant differ-
ence in the group effect (patients versus
controls) between different ETDRS
grid subfields (p < 0.0001) in the OLC.
The significant differences [95% confi-
dence interval] of the estimated LS
means (controls minus patients) for the
ETDRS subfields were all between
3.76 lm [5.53; 2] (central,
p < 0.0001) and 1.89 lm [3.65;
0.12] (outer nasal, p = 0.0366), with
the strongest difference in the central
subfield. Although all nine ETDRS
subfields showed lower thickness values
for control than patient participants,
some differences were not statistically
significant. The subfields with no statis-
tically significant difference were inner
top, inner nasal and outer top. Table 2
shows values of all ETDRS subfields,
including absolute values. These find-
ings support Hypothesis 3 for OLC and
a diffuse swelling of the outer nuclear
layer in the patient group.
Summary of clinically relevant results
1 The hypothesized diffuse swelling of
GCL in the entire macula probably is
an early sign of DME.
2 The hypothesized diffuse swelling of
OLC, most likely in the outer nuclear
layer, strongest in the central millimetre
around the fovea, may be associated
with early DME.
Discussion
We compared the layer thicknesses of
five different retinal layers in a group of
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Fig. 3. Box plots of mean layer thicknesses of the nerve fibre layer (NFL, layer 1), a complex of the
ganglion cell and inner plexiform layers (GCIPL, layer 2), inner nuclear layer (INL, layer 3), a
complex of outer plexiform layer, outer nuclear layer, external limiting membrane until
photoreceptor inner segments begin, referred to as the outer layer complex (OLC, layer 4) and
photoreceptors (PR, layer 5) in patient (1) versus control participants (0) in the entire early
treatment diabetic retinopathy study (ETDRS) grid (left) and just the central millimetre subfield
(ETDRS 1) of the ETDRS grid (right).
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patients with DM1 well-controlled with
intensified insulin therapy since diagno-
sis and an age- and sex-matched control
group in a large group of 300 study
participants with 600 eyes included in
the study. We analysed 49 b-scans of
each patient in high-speed mode (512 a-
scans), resulting in a very large amount
of data points. With this high number
of data points, we found significant
differences between the patient and
control groups in four out of five layers.
Having regard to the physiological dis-
tribution of the layers, we conclude only
two of these findings are clinically
relevant. The other differences although
statistical significance are too small and
cannot be explained by our current
knowledge of pathophysiology.
We found that the NFL is in mean
0.7 lm [1.34; 0.05] thinner in the
healthy than in the diabetes group.
Other studies have reported opposite
results. Many of these did not distin-
guish patients with DM1 from those
with DM2. Srinivasan et al. (2016a, b)
maintained patients with DM1, DM2
or no classification could be assessed
for the NFL in a single group. There-
fore, we discuss studies in both DM1
and DM2. Furthermore, most studies
investigated the NFL around the optic
disc in a circular scan pattern (Park
Table 2. Values of all ETDRS grid subfields’ absolute LS-mean thicknesses for a complex of the ganglion cell and inner plexiform layers (GCIPL),
inner nuclear layer (INL) and a complex of the outer plexiform layer, outer nuclear layer, external limiting membrane until photoreceptor inner
segments begin (OLC) layer for patients and controls and the differences in LS-mean thicknesses of the same layers between them; negative differences
mean patients’ layers are thicker than control participants’.
Subfield Layer LS-mean thickness patients LS-mean thickness controls Difference Lower 95% CI Upper 95% CI p-value
Central millimetre GCIPL 39.34* 36.47* 2.87 4.25 1.47 <0.0001
Inner top 97.25 92.98 4.27 5.66 2.88 <0.0001
Inner temporal 92.31 89.78 2.52 3.92 1.13 0.0004
Inner bottom 96.52 92.80 3.72 5.11 2.32 <0.0001
Inner nasal 97.29 93.78 3.51 4.90 2.12 <0.0001
Outer top 64.51 61.09 3.42 4.81 2.03 <0.0001
Outer temporal 70.96 66.87 4.08 5.48 2.69 <0.0001
Outer bottom 62.09 58.28 3.81 5.20 2.42 <0.0001
Outer nasal 70.89 65.74 5.15 6.54 3.76 <0.0001
Central millimetre INL 21.46* 20.88* 0.58 1.31 0.15 0.1191
Inner top 43.66 45.03 1.37 0.64 2.1 0.0002
Inner temporal 40.95 41.54 0.59 0.14 1.32 0.1123
Inner bottom 43.08 44.97 1.89 1.16 2.62 <0.0001
Inner nasal 43.40 44.09 0.69 0.05 1.42 0.0659
Outer top 32.97 33.37 0.4 0.33 1.13 0.2873
Outer temporal 34.66 35.52 0.86 0.13 1.59 0.0217
Outer bottom 32.08 32.96 0.88 0.15 1.61 0.0182
Outer nasal 34.96 35.93 0.97 0.24 1.7 0.0091
Central millimetre OLC 142.23* 138.47* 3.76 5.53 1.99 <0.0001
Inner top 118.85 117.40 1.46 3.23 0.31 0.1065
Inner temporal 120.95 118.71 2.23 4 0.47 0.0133
Inner bottom 116.89 114.61 2.28 4.05 0.51 0.0115
Inner nasal 123.54 122.16 1.38 3.15 0.39 0.1255
Outer top 104.17 102.64 1.53 3.3 0.24 0.0896
Outer temporal 102.09 99.57 2.52 4.29 0.75 0.0053
Outer bottom 95.94 93.79 2.16 3.93 0.39 0.0169
Outer nasal 102.43 100.54 1.89 3.66 0.12 0.0366
CI = Confidence interval of the difference.
Bold indicates the significance level (p < 0.05).
* The slight difference to the reported descriptive values in the central millimetre can be attributed to the exclusion of extreme outliers.
Table 1. Values of all ETDRS grid subfields’ absolute LS-mean total retinal thicknesses for patient and control participants and the differences of the
LS-mean thicknesses between them; negative differences mean patients’ retinas are thicker than control participants’.
Subfield LS-mean thickness patients LS-mean thickness controls Difference Lower 95% CI Upper 95% CI p-value
Central millimetre 266.10 262.54 3.56 6.89 0.23 0.0362
Inner top 333.74 329.38 4.36 7.69 1.03 0.0103
Inner temporal 320.93 316.25 4.67 8.01 1.34 0.0060
Inner bottom 331.76 326.38 5.38 8.71 2.05 0.0016
Inner nasal 335.85 330.90 4.95 8.29 1.62 0.0036
Outer top 287.15 281.38 5.76 9.09 2.43 0.0007
Outer temporal 272.77 265.64 7.13 10.46 3.80 <0.0001
Outer bottom 277.04 268.80 8.24 11.57 4.90 <0.0001
Outer nasal 306.03 297.11 8.91 12.24 5.58 <0.0001
CI = confidence interval of the difference.
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et al. 2011; Shahidi et al. 2012; Carpi-
neto et al. 2016; Chen et al. 2016; El-
Fayoumi et al. 2016; Gundogan et al.
2016, 2016) and are not comparable
with our study. We considered macular
NFL thickness a more robust variable
because thickness values for peripapil-
lary NFL can be particularly easily
misinterpreted as they heavily dependent
on total retinal thickness (Yang et al.
2017) and vessels can lead to overesti-
mation of thickness. A few studies have
investigated macular NFL thickness,
and some reported thinning of the
NFL. van Dijk et al. (2012) analysis of
8 retinal layers in 64 patients with no or
minimal signs of DR and 57 healthy
participants revealed a significant differ-
ence in NFL thickness between patients
with minimal DR and healthy partici-
pants with an absolute difference of
1.9 lm [0.3; 3.5]: The control had
thicker NFL than the patient group,
contrary to our mean finding. Chhablani
et al. (2015) found the macular NFL in
mean to be similar between 76 eyes of 62
treatment-na€ıve patients with DM and
with or without DR and 67 eyes of 66
age-matched healthy participants but
the minimum value was significantly
lower in the DM group. This is not
exactly what we found but our conclu-
sion is the same: NFL is not altered in
patients with DM with/without DR
compared with healthy eyes. Chhablani’s
group also found the minimum thickness
was less in eyes with DM (9.41–10.2 lm)
than in healthy eyes (13.16 lm). They
measured thickness in radial sectors
while we measured it in ETDRS sub-
fields. We found the minimum NFL
thickness was lower in the central 3-mm
subfields but it was higher in DM than in
healthy eyes in the 3–6-mm ring around
the centre (see Table S1). This indicates
there is actually no difference in the NFL
thicknesses of any of the groups, as
found by Park et al. and Srinivasan
et al. who analysed 126/143 eyes of
patients with diabetes compared with
40/42 healthy participants. Both studies
found no significant difference in macu-
lar thickness NFL values between the
control and DM group with no (mild)
signs of DR, (Park et al. 2011; Srinivasan
et al. 2016a,b) similar to our cohort.
We also found thickening of the
GCIPL in our patients and hypothesized
a diffuse swelling as an early sign of
DME. Wanek et al. found significant
thickening of the GCIPL in 29 patients
with DM and no or mild
nonproliferative DR compared with 22
control participants, as in our study. By
contrast, other researchers report a gen-
eral GCIPL thinning rather than a
thickening in patients with DM (Srini-
vasan et al. 2016a,b). Many factors need
to be considered when measuring indi-
vidual layer thicknesses. Srinivasan
et al. concluded GCIPL thickness was
reduced in 84/67 patients with DM1/2
compared with 42 healthy participants.
Closer examination reveals the patients
with DM1 had a thickness of
97  8 lm, with DM2 93  8 lm and
healthy participants 96  7 lm. Gan-
glion cell and inner plexiform layer
(GCIPL) thickness was therefore
reduced in DM2 but not different or
even thickened in DM1, as found in our
study. Participants were not matched for
age/sex, group sizes were uneven and
35%–46% of patients had signs of DR
but how this was evaluated is not stated
(Srinivasan et al. 2016a,b). Interestingly,
it was this group who maintained tissue
thickness can be measured in DM1 and
DM2 interchangeably. Although possi-
bly true for other layers, it is not true for
GCIPL. This is also shown by Chen
et al. who analysed different retinal
layers and reported a significant thinning
of 4–5 lm of the GCIPL in patients with
DM1 compared with age- and sex-
matched healthy eyes but the study
group was small (26 DM1, 34 DM2
without DR) and the study possibly
underpowered. A study by El-Fayoumi
et al. in children with DM1 might
explain why our findings contrast with
studies reporting GCIPL thinning in
patients with DM2. They found children
with dyslipidaemia had a thinned
GCIPL thickness, whereas patients with
normal blood lipids had a thickness
similar to the control group (El-Fayoumi
et al. 2016). Given that many of the
studies where GCIPL was thinned were
in patients with DM2 (van Dijk et al.
2012; Chhablani et al. 2015; Carpineto
et al. 2016; Ng et al. 2016), where lipid
profiles are known to be worse than in
DM1 (Duca et al. 2013), dyslipidaemia
may have been a confounder in the DM2
studies that was reduced by our well-
controlled patient group as patients with
DM1 have been shown to have signifi-
cantly less dyslipidaemia than healthy
people (Wadwa et al. 2005). Regarding
absolute values in mean, the GCIPL
thickness of patients with hyperlipidemia
was 6 lm less than in patients with no
hyperlipidemia (El-Fayoumi et al. 2016).
Our GCIPL thickening was only 3.6 lm.
This could indicate that the thinning in
other studies was due to hyperlipidemia
and the GCIPL thickening was masked.
In general, we hypothesize also that
GCIPL thickening is greater in patients
developing DME later and the GCIPL is
unaltered in patients who remain with-
out oedema. This must be proven in a
follow-up analysis of our patients.
Finally, our hypothesis may not hold
as we measured the GCIPL complex
rather than just the ganglion cell layer
(GCL), as is commonly done because
segmentation is easier. Possibly there-
fore while the GCL thins the inner
plexiform layer (IPL) thickens. But
taking account of our arguments men-
tioned above and as we found no
literature reporting IPL thickening as
an early change in DR, we believe we
saw GCL rather than IPL thickening.
Both our and reported data strongly
indicate DR changes are multifactorial
(Jonsson et al. 2016), and two pathways
can be seen in the GCL – the neurode-
generative pathway, where a slow thin-
ning of the GCL might be present due
to atrophy of neurons, and the vascular
pathway, where a thickening of the
GCL might be an early indication for
the development of DME with leaking
vessels and diffuse and cystoid oedema.
A retrospective analysis when DME
development is known in the patients
after a few years is needed to prove this.
One reason why especially in our
cohort neurodegeneration is not/less
seen in the form of mean NFL or
GCIPL thinning could be that our
patients received an intensified insulin
therapy from the day of their diabetic
disease diagnosis. A neuroprotective
role of insulin to rescue retinal neurons
from apoptosis by a phosphatidylinos-
itol 3-kinase/Akt-mediated mechanism
that reduces the activation of caspase-3
has been shown (Barber et al. 2001).
We found in mean the INL was
thinner in patients with diabetes than in
healthy participants. Although reported
before for patient groups similar to ours
(DM1 with no (n = 32) or minimal
(n = 25) DR), (van Dijk et al. 2009;
Chen et al. 2016) we believe this finding
has no clinical relevance as we cannot
explain why this thinning should not be
the same over the entire macular region.
In our study, we could neither find a
general thinning nor a circled rule
around the fovea for this thinning. We
have not found support from the
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literature, except in van Dijk et al. ‘s
study with few patients. But Scarinci
et al. (2017) recently reported a signif-
icant INL thickening in 76 patients with
diabetes (DM1, no signs of DR) and
Vujosevic & Midena (2013) reported
increased INL thickness in 74 patients
with diabetes and no or initial DR.
Chen et al. (2016) concluded INL thick-
ens in DM2 and INL thins in DM1. In
sum, the available data from the liter-
ature and our study are too inconclusive
to resolve the issue.
As in previous studies (Vujosevic &
Midena 2013), we found that a signifi-
cant thickening in the OLC (a complex
mostly containing the outer plexiform
and nuclear layers (OPL, ONL)), in
patients with diabetes, most pronounced
in the centre where DME usually starts.
Chen et al. reported a significant para-
and perifoveal thinning in the ONL of
patients with DM1 compared with
healthy participants and ONL thicken-
ing only in patients with DM2. On
closer scrutiny, it is evident that these
areas were thinned in patients with DM1
but the foveal area was thickened, sup-
porting our hypothesis that the diffuse
swelling in the ONL starts in the central
area. Chen et al. found thickening
everywhere in the ONL in DM2.
Maybe, their finding of thinning of the
para- and perifoveal areas in DM1 was
due to chance and their small sample
(Chen et al. 2016). Wanek et al.
reported a significant thinning of the
OPL and thickening of the ONL,
strengthening our hypothesis that the
ONL is the layer affected in our complex
and the OPL has only a minor role.
The PR layer has been reported not
to change in diabetes (Vujosevic &
Midena 2013; Wanek et al. 2016) and
from a pathophysiological view, alter-
ations in this layer are hardly a marker
for early signs of DR or DME. In the
one publication about thinning of the
PR layer in patients with diabetes, PR
thickness was only measured at one
unstandardized point of interest and it
is doubtful that the results reported are
reproducible with less variance than the
reported 7 lm difference between the
groups (Verma et al. 2009). In our
opinion, the PR layer becomes more
important for changes under therapy,
both laser and anti-angiogenic therapy,
and late changes of resolved oedema.
The strengths of our study are the
large dataset (600 eyes), a well-con-
trolled clinically homogenous group of
only patients with DM1 (many studies
used mixed groups) and a standard-
ized, blinded and quality-controlled
reading centre evaluation. In general,
comparison of published studies with
our analysis is difficult as most studies
have either used a fully automated
segmentation without any corrections
(van Dijk et al. 2012; Chhablani et al.
2015; Carpineto et al. 2016; Chen et al.
2016; El-Fayoumi et al. 2016; Gundo-
gan et al. 2016; Ng et al. 2016) or
solely a manual measurement of single
points, which is usually quite erroneous
(Browning et al. 2007; Verma et al.
2009). We used a fully automated
segmentation but then corrected each
layer on each b-scan manually. Every
single raster scan needed correction. It
must remember, especially with regard
to significances throughout all studies
around no more than 1–6 lm (e.g.
1.9 lm in [van Dijk et al. 2012; ]) of
thickness differences, that a pixel differ-
ence is usually already a few microme-
tres. Therefore, even a segmentation
that looks good might not be good
enough, especially in healthy cases.
Also, not all studies were matched.
Some were matched for age (van Dijk
et al. 2009, 2012; Verma et al. 2009;
Shahidi et al. 2012; Chhablani et al.
2015; Chen et al. 2016; El-Fayoumi
et al. 2016; Ng et al. 2016; Srinivasan
et al. 2016a,b) and few for sex, (van
Dijk et al. 2009, 2012; Chen et al. 2016;
El-Fayoumi et al. 2016) which is of
critical importance. Sex-specific findings
of greater macular retinal thickness in
men than in women, in the centre, inner
ring and outer temporal ring ETDRS
grid areas have been found and taken
into consideration by many studies
analysing retinal layers in other diseases
(Ooto et al. 2015); age is negatively
correlated with inner retinal thickness
(Ooto et al. 2011, 2015).
Another limitation of our study is
the use of one time-point only and the
different times of onsets of diabetes
between patients, which is hard to
standardize and will probably always
be a weakness in such studies.
In conclusion, we believe GCL and
OLC thickening are an early sign of
DME in patients with diabetes with
and without signs of DR. Further
analyses are needed to find if this is
only true for a subgroup of patients or
a general finding. Our results suggest
that the thickening could be an early
sign for diffuse swelling and an arising
DME, which could be shown by a
follow-up analysis.
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may be found in the online version of
this article:
Table S1 Values of all ETDRS grid
subfields’ mean thicknesses (and stan-
dard deviations) of five retinal layers
(nerve fiber layer (NFL), a complex of
the ganglion cell and inner plexiform
layers (GCIPL), inner nuclear layer
(INL), a complex of outer plexiform
layer, outer nuclear layer, external lim-
iting membrane until photoreceptor
inner segments begin, referred to as the
outer layer complex (OLC) and pho-
toreceptors (PR) and total retinal thick-
ness in patient and control participants.
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